C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.
Toshiharu MorikawaTaku NaikiYosuke SugiyamaAya Naiki-ItoTakashi NagaiToshiki EtaniKeitaro IidaTeruki IsobeYusuke NodaNobuhiko ShimizuMaria AokiMasakazu GondaRika BannoHiroki KubotaRyosuke AndoYukihiro UmemotoNoriyasu KawaiTakahiro YasuiPublished in: Cancers (2024)
Our study provides real-world data showing that enfortumab vedotin prolonged survival in Asian patients similar to the EV-301 trial. Additionally, the C-reactive protein level might be considered a prognostic marker of enfortumab vedotin therapy in such patients.